Inozyme Pharma announced dosing of the first patient in its ENERGY-1 trial, a Phase 1b clinical trial of INZ-701 in infants with ENPP1 Deficiency. “Initiation of the ENERGY-1 trial in infants is an important milestone as we continue to advance INZ-701 with the goal of improving the lives of patients with ENPP1 Deficiency across all age groups. We are committed to a global program to identify and treat all newborns with this condition,” said Kurt Gunter, M.D., senior vice president and chief medical officer of Inozyme.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on INZY:
- Inozyme Pharma Announces Dosing of First Infant with ENPP1 Deficiency in a Phase 1b Trial of INZ-701
- Inozyme Pharma to Present at the Jefferies Healthcare Conference
- Inozyme Pharma Reports First Quarter 2023 Financial Results and Provides Business Highlights
- INZY Earnings this Week: How Will it Perform?
- Inozyme reports inducement grants under Nasdaq listing rule